Biomarker ID | 804 |
PMID | 22077694 |
Year | 2011 |
Biomarker | Methylation of GSTP1 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Hypermethylated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include: Biological oxidations, Metapathway biotransformation, Pathways in cancer, T cell receptor regulation of apoptosis, Metabolism |
Experiment | negative histology followed by a positive biopsy more than 24 months later |
Type of Biomarker | Prognostic |
Cohort | 86 men with an initial histologically negative prostate biopsy were chosen for repeat biopsy |
Senstivity | (group 1 + Group 3) = 0.43 (0.22–0.66); (group 1 + Group 2) = 0.36 (0.11–0.69) |
Specificity | (group 1 + group 3) : 0.75 (0.63–0.85); (group 1 + Group 2) = 0.86 (0.73–0.94); |
AUC | All 3 groups: 0.62 (95% CI 0.51–0.72) |
Accuracy | (group 1 + group 3) : [TP: 9 FN: 12 TN: 49 FP: 16]; (group 1 + Group 2) = [TP: 4 FN: 7 TN: 42 FP:7 ] |
Level Of Significance | NA |
Method Used | Quantitave Methylation Specific PCR |
Clinical | No |
Remarks | Patients were divided into 3 risk groups on the basis of cancer incidence. Cancer incidence (determined by repeat biopsy) was 24% (21/86); within Groups 1, 2 and 3 the incidence was 14%, 21%, and 39%, respectively. Group 1: suspicious DRE or high-risk PSA level (PSA ≥ 8.0 ng/mL and prostate volume <50.0 mL, PSA density ≥0.2 ng/mL/cm , or percent free PSA (%fPSA) ≤ 10.0); Group 2: high-grade prostatic intraepithelial neoplasia (HGPIN); Group 3: atypical small acinar proliferation (ASAP) on initial biopsy. |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | GSTP1 |